Cargando…
Ex vivo-expanded highly pure ABCB5(+) mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data
BACKGROUND AIM: Mesenchymal stromal cells (MSCs) hold promise for the treatment of tissue damage and injury. However, MSCs comprise multiple subpopulations with diverse properties, which could explain inconsistent therapeutic outcomes seen among therapeutic attempts. Recently, the adenosine triphosp...
Autores principales: | Kerstan, Andreas, Niebergall-Roth, Elke, Esterlechner, Jasmina, Schröder, Hannes M., Gasser, Martin, Waaga-Gasser, Ana M., Goebeler, Matthias, Rak, Katrin, Schrüfer, Philipp, Endres, Sabrina, Hagenbusch, Petra, Kraft, Korinna, Dieter, Kathrin, Ballikaya, Seda, Stemler, Nicole, Sadeghi, Samar, Tappenbeck, Nils, Murphy, George F., Orgill, Dennis P., Frank, Natasha Y., Ganss, Christoph, Scharffetter-Kochanek, Karin, Frank, Markus H., Kluth, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310651/ https://www.ncbi.nlm.nih.gov/pubmed/33011075 http://dx.doi.org/10.1016/j.jcyt.2020.08.012 |
Ejemplares similares
-
Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers
por: Kerstan, Andreas, et al.
Publicado: (2022) -
Allogeneic ABCB5(+) Mesenchymal Stem Cells for Treatment-Refractory Chronic Venous Ulcers: A Phase I/IIa Clinical Trial
por: Kerstan, Andreas, et al.
Publicado: (2021) -
In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials
por: TAPPENBECK, NILS, et al.
Publicado: (2019) -
Process data of allogeneic ex vivo-expanded ABCB5(+) mesenchymal stromal cells for human use: off-the-shelf GMP-manufactured donor-independent ATMP
por: Ballikaya, Seda, et al.
Publicado: (2020) -
Process development and safety evaluation of ABCB5(+) limbal stem cells as advanced-therapy medicinal product to treat limbal stem cell deficiency
por: Norrick, Alexandra, et al.
Publicado: (2021)